To assess the association between cytomegalovirus (CMV) serology of donor and recipient and adverse outcomes after liver transplantation in the era of effective antiviral chemoprophylaxis.
OBJECTIVE:
To assess the association between cytomegalovirus (CMV) serology of donor and recipient and adverse outcomes after liver transplantation in the era of effective antiviral chemoprophylaxis.
PATIENTS AND METHODS:
We performed a retrospective cohort study of 193 consecutive patients undergoing their first liver transplantation between February 1998 and July 2000 with targeted and preemptive ganciclovir chemoprophylaxis. Patients were divided into 4 groups by CMV serology of donor and recipient: donor-/recipient-; donor-/recipient+; donor+/recipient+; and donor+/recipient-. Survival to the end points of retransplantation, death, or survival to 1 year after transplantation (whichever occurred first) was assessed. Rates of bacterial, fungal, and CMV infection and of CMV disease were recorded and compared.
RESULTS: No significant differences were observed in the rates of retransplantation, death, or survival to 1 year among the 4 groups of patients. Despite significantly higher rates of CMV infection in the donor+ groups, there were no differences in the rates of bacterial or fungal infection or of CMV disease. Rejection occurred least frequently in the donor-/recipient-group.
CONCLUSION:
The adverse effects of CMV on outcomes after liver transplantation have been diminished in the era of effective antiviral chemoprophylaxis.
Mayo Clin Proc. 2006;81 (8) :1029-1033 C ytomegalovirus (CMV) has been associated with adverse outcomes after liver transplantation. Cytomegalovirus serology of donor and recipient affects survival after liver transplantation. [1] [2] [3] Donor CMV seropositivity and CMV infection after transplantation increase the recipient's risk for bacterial and fungal infection. [4] [5] [6] [7] Also, CMV disease increases the cost of care after liver transplantation. 8 These adverse effects of CMV on outcomes after liver transplantation were first observed at a time when effective anticytomegaloviral chemoprophylaxis was not provided routinely after transplantation.
A large randomized, placebo-controlled trial demonstrated the effectiveness of orally administered ganciclovir for preventing CMV infection and disease after liver transplantation. 9 The effectiveness of this prophylaxis for improving other adverse outcomes associated with CMV was not examined, although no difference in survival was observed between the treated and the placebo groups 12 months after transplantation.
The purpose of the current study was to assess the effect of CMV serogroup on outcomes shown to be associated with CMV among patients undergoing liver transplantation and receiving targeted and preemptive ganciclovir chemoprophylaxis. Only patients undergoing their first liver transplantation were included in the study for 2 reasons: to eliminate the effects of additional immunosuppression and retransplantation on infection and survival and to prevent crossover of patients between CMV serogroups.
PATIENTS AND METHODS
This study was approved by the Mayo Foundation Institutional Review Board. One hundred ninety-three consecutive patients undergoing their first liver transplantation between February 1998 and July 2000 at the Mayo Clinic in Jacksonville, Fla, were followed up to retransplantation, to death, or to survival at 1 year, whichever occurred first. Patients were divided into 4 groups by CMV serology of donor and recipient: donor-/recipient-; donor-/recipient+; donor+/recipient+; and donor+/recipient-. Risk factors for infection and for death before, during, and after transplantation were collected from review of medical records and transplant center databases. Episodes of bacterial, fungal, and CMV infection and of CMV disease before retransplantation, death, or survival to 1 year after transplantation were identified by review of medical and clinical microbiology records. Standard definitions were used for bloodstream infection, pneumonia, urinary tract infection, surgical site infection, and cholangitis caused by bacteria or fungi. 10, 11 Bacterial or fungal infections that did not meet these criteria were labeled as miscellaneous. Cytomega-lovirus infection was defined as the recovery of CMV in shell vial culture. Cytomegalovirus disease was defined on the basis of recently proposed criteria. 12 The date of diagnosis of each infection relative to the date of transplantation was recorded and used for the time-to-event analysis.
Surgical and medical management other than prophylactic ganciclovir therapy was not directed or affected by the CMV serology of the donor and the recipient. All patients were given ceftizoxime-or in the event of β-lactam antibiotic allergy, vancomycin and aztreonam-for perioperative antibiotic prophylaxis beginning immediately before and continuing through 48 hours after liver transplantation. All patients also were given nystatin oral solution (5 mL swish and swallow) for the first 30 days after transplantation. Patients who were CMV seronegative and received a liver allograft from a CMV-seronegative donor (donor-/recipient-) were given either leukoreduced blood products or blood products collected exclusively from CMV-seronegative blood donors. Immunosuppressive therapy for all patients included tacrolimus, prednisone, and mycophenolate mofetil or azathioprine. Acute cellular rejection was determined by histologic assessment of liver tissue.
As soon as enteral or oral administration of medications was feasible after transplantation, targeted ganciclovir prophylaxis was given (1 g, orally or via nasogastric tube, 3 times daily) to all CMV-seronegative patients who received a liver allograft from a CMV-seropositive donor (donor+/recipient−). Ganciclovir was continued for 100 days after transplantation. All other patients were given acyclovir (400 mg), orally or via nasogastric tube, twice daily for the first 30 days after transplantation. Shell vial cultures of blood for recovery of CMV were performed weekly on all patients for the first 8 weeks after transplantation and once during the fourth month after transplantation. 13 In addition, shell vial cultures were performed on all liver biopsy specimens after transplantation, including scheduled biopsies at 7 days and 4 months after transplantation. This monitoring allowed for preemptive therapy for CMV infection not associated with CMV disease. If CMV was recovered in shell vial culture in the absence of CMV disease, ganciclovir was given intravenously in a dosage of 5 mg/kg every 12 hours for 14 days; dosages were reduced for renal insufficiency. Clinicians were able to request additional shell vial cultures of blood, urine, and endoscopic biopsy and respiratory secretion specimens when CMV disease was suspected at times other than the scheduled shell vial testing. Ganciclovir was given intravenously in longer duration, at the discretion of the treating physician, if CMV disease was present. Ganciclovir also was given intravenously in a dosage of 5 mg/kg every 12 hours during administration of antilymphocyte globulin treatment for corticosteroid-resistant rejection; appropriate adjustments were made for renal insufficiency. Ganciclovir was not administered orally for treatment of CMV infection or disease.
Kaplan-Meier estimates were used for time-to-event analyses and calculation of 6-month and 12-month event rates. For the end point of death, survival times were censored at retransplantation or at the maximum follow-up time of 1 year if these preceded death. For the retransplantation end point, survival times were censored at death or at 1 year of follow-up if these preceded retransplantation. For all other events, patient data were censored at death, retransplantation, or 1 year of follow-up. The associations between CMV serology and end points were evaluated with log-rank tests. Time-to-event analyses were performed with S-PLUS version 6.1 (Mathsoft, Seattle, Wash).
The associations between CMV serostatus and categorical patient characteristics were evaluated by using 2-sided Fisher exact tests. For continuous characteristics, the association was evaluated by using 2-sided Kruskal-Wallis tests. These nonparametric methods were used because some tables were sparse and some response variables were skewed. These analyses were performed with SAS version 8.2 software (SAS Institute Inc, Cary, NC).
RESULTS
Characteristics that are typically associated with infection and with death before, during, and after liver transplantation are shown in Table 1 . These characteristics were analyzed for differences between groups of CMV serologies. The fresh-frozen plasma requirements were lower in the CMV donor-/recipient-group (median, 6.5 vs 10-12 units, P=.006), and greater platelet transfusion requirements were observed in the CMV donor-/recipient-and CMV donor+/ recipient+ groups (median, 12 vs 6 units, P=.01). A lower frequency of rejection episodes requiring treatment with corticosteroids was observed in the CMV donor−/recipient− group (23% vs 45%-51%, P=.04). Statistical analysis of antilymphocyte globulin treatment of corticosteroid-resistant rejection was not performed because only 2 patients were treated in this fashion.
The number of patients in each CMV serogroup who died or required retransplantation is indicated in Table 2 , as is the number in whom bacterial infection, fungal infection, CMV infection, or CMV disease developed. The estimated probabilities of death, retransplantation, bacterial infection, fungal infection, CMV infection, and CMV disease for each CMV serogroup are also provided at 6 and 12 months. Despite a significant difference in the risk of CMV infection among the 4 CMV serogroups (P=.008), there were no differences in the rates of death (P=.93), retransplantation (P=.17), bacterial infection (P=.94), fungal infection (P=.38), or CMV disease (P=.12) among the 4 groups. The rate of retransplantation was higher in the CMV donor+/ recipient-serogroup (19% vs 5%-10%), although the difference was not statistically significant.
The causes of graft failure and retransplantation in each serogroup are shown in Table 3 .
DISCUSSION
The risk of CMV infection and disease is greatest during the first 3 months after liver transplantation, when immunosuppressive therapy is routinely the most intense. 5 Independent of immunosuppression, CMV-seronegative patients who receive an allograft from CMV-seropositive donors (donor+/recipient-) are at the highest risk for CMV infection and disease. 5 Recognition of these risks has directed methods for prevention and early detection of CMV infection after transplantation.
In our cohort, targeted ganciclovir prophylaxis was given for the first 100 days after transplantation to the group of patients at greatest risk for CMV infection (donor+/recipient-). In the other serogroups, shell vial cultures of blood and of liver biopsy specimens were collected at regular intervals to allow for preemptive therapy for CMV infection not associated with CMV disease. When these targeted and preemptive strategies to prevent CMV disease were used in the current era of liver transplantation, the adverse effect of CMV serology on survival after transplantation was no longer observed. Similarly, when this comprehensive strategy for antiviral chemoprophylaxis was used, the adverse effect of donor CMV seropositivity on bacterial and fungal infection after transplantation was no longer observed. Finally, these attenuations of the previously reported adverse effects of CMV on survival and bacterial and fungal infection after liver transplantation were achieved despite a greater rate of CMV infection in the donor+ groups.
The reduction in the frequency of death, retransplantation, bacterial infection, fungal infection, and CMV disease in the donor-/recipient+, donor+/recipient+, and donor+/ recipient-CMV serogroups, relative to the donor-/recipient-CMV serogroup, does not eliminate concern for the adverse effect of CMV on outcomes after transplantation. The consequences of CMV infection and CMV disease were not separately examined in the current study. Also, the adverse clinical outcomes associated with CMV may be more difficult to detect in the current era of liver transplantation because the overall rates of some of these outcomes, such as graft loss and patient death during the first year, are If no events occurred, the estimated probability is zero and a confidence interval is not reported. ‡Number of events by 12 mo excludes events observed after censoring. §Confidence interval is based on <5 events and should be interpreted cautiously.
lower than those reported in the early era of transplantation. The size of the cohort examined in this study may have been too small to confirm a lingering, statistically significant association between graft loss and the donor+/recipient-CMV serogroup, for which there was a trend toward early retransplantation (19% vs 5%-10%, P=.17). Similarly, the adverse consequences of CMV will become more difficult to detect as the frequencies of CMV infection and disease are reduced by comprehensive, effective, preemptive, and prophylactic antiviral interventions. For all these reasons, the decreased frequency of corticosteroid treatment for rejection in the donor-/recipient-group and the higher rate of retransplantation in the donor+/recipientgroup merit further investigation. Acute rejection and hepatic artery thrombosis after liver transplantation have previously been associated with CMV infection. 3, 14 In the current study, the rate of rejection requiring corticosteroid therapy in the CMV donor+ or recipient+ groups was still significantly higher than the donor−/recipient− group, just as the rates of CMV infection were higher in the donor+ or recipient+ groups. Furthermore, despite a decrease in the frequency of hepatic artery thrombosis in the donor+/recipient-group to 2.2% (1/45) with the use of effective antiviral chemoprophylaxis (vs 12.5% reported previously, before the use of ganciclovir 14 ), this group was the only one in which hepatic artery thrombosis occurred, and it had the highest rate of CMV infection. Studies are needed to determine whether the rate of acute rejection in CMV donor+ or recipient+ liver transplant recipients or the rate of hepatic artery thrombosis and other causes of graft loss in CMV donor+/recipient-recipients during the first year can be Serogroup † reduced by (1) combining antiviral chemoprophylaxis with immunologic therapies such as CMV hyperimmune globulin; (2) providing universal anticytomegaloviral chemoprophylaxis for more than the first 100 days after transplantation; or (3) employing preemptive antiviral strategies that use surveillance with antigen or gene detection to identify CMV infection at stages earlier than those identified by shell vial culture.
Because of differences in immunosuppression and in the burden of CMV transmitted by different organs, the antiviral chemoprophylaxis strategy used after liver transplantation may not be directly applicable to other solid organ transplantations. However, the principle that the adverse consequences of CMV are decreased in the setting of a comprehensive antiviral chemoprophylaxis strategy is supported by our observations and those made recently at other centers. Singh et al 15 reported that, in patients at their institution with CMV infection after liver transplantation who were treated preemptively, the incidence of bacterial or fungal infections and survival from 6 months to 3 years after transplantation were not significantly different from the incidence of these outcomes in patients without CMV infection who did not receive antiviral prophylaxis. MunozPrice et al 16 reported a decrease in the frequency of bacteremia after liver transplantation associated with ganciclovir prophylaxis. Decreased frequencies of rejection and graft loss in kidney, heart, and lung transplant recipients have also been reported after the introduction of CMV antiviral chemoprophylaxis.
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CONCLUSION
The adverse consequences previously associated with CMV serology after liver transplantation are decreased in the current era of transplantation when comprehensive antiviral chemoprophylaxis is used. Identifying the effects of CMV on clinical outcomes after liver transplantation will be more difficult to discern in the presence of antiviral chemoprophylaxis.
